FDA approves Novo's Rebinyn for hemophilia B

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said FDA approved a BLA for Rebinyn nonacog beta pegol to treat and control bleeding in patients with hemophilia B. Specifically, the therapy is approved for on-demand treatment and control of bleeding episodes and the perioperative management of bleeding around the time of surgery in adults and children.

Novo intends to launch the product in 1H18...